Abstract
Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have